CellThera AI
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $70M
Overview
An AI-driven biotech using machine learning to engineer next-generation, optimized cell therapies.
OncologyAutoimmune Diseases
Technology Platform
A proprietary AI and machine learning platform that models biological systems to design and optimize the therapeutic function, safety, and manufacturability of engineered cell therapies.
Funding History
1Total raised:$70M
Series D$70M
Opportunities
Potential to significantly reduce the time and cost of developing more effective and safer cell therapies through predictive AI design.
Risk Factors
High risk of technological validation, as the AI models must accurately predict complex human biology to succeed in clinical trials.
Competitive Landscape
Competes with other AI-for-drug-discovery companies like Exscientia and Recursion, as well as traditional cell therapy developers, by offering a specialized AI platform for cell engineering.